Burčík Denis, Macko Ján, Podrojková Natália, Demeterová Jana, Stano Michal, Oriňak Andrej
University of P. J. Safarik in Kosice, Faculty of Sciences, Institute of Chemistry, Department of Physical Chemistry, Moyzesova 11, 041 01 Kosice, Slovakia.
ACS Omega. 2025 Feb 9;10(6):5193-5213. doi: 10.1021/acsomega.4c08140. eCollection 2025 Feb 18.
Intercellular adhesion is accompanied by several physical quantities and actions. In this review, we tried to collect information about the influence of surface energy and its impact on cell-cell adhesion. It still undergoes development for cancer treatment. Data on receptor-ligand interactions that occur on circulating tumor cells (CTCs) are described, and adhesion receptors as therapeutic targets are collected. Additionally, the impact of surface roughness on the interactions between CTC cells and the surface was monitored. The effects of different cell adhesion molecules (CAMs) on cell adhesion, growth, and proliferation were investigated. This review offers general principles of cell adhesion, through the blockade of adhesion with blocking drugs and inhibitors like computational models that describe the process of adhesion. Some theoretical models based on the minimum of the total free energy of interaction between CAMs and selected organic molecules have been presented. The final aim was to find information on how modulation of the surface of CTCs (by medicals or physically) inhibits cancer metastases formation.
细胞间黏附伴随着多种物理量和行为。在本综述中,我们试图收集有关表面能的影响及其对细胞间黏附的作用的信息。它在癌症治疗方面仍在不断发展。描述了循环肿瘤细胞(CTC)上发生的受体 - 配体相互作用的数据,并收集了作为治疗靶点的黏附受体。此外,还监测了表面粗糙度对CTC细胞与表面之间相互作用的影响。研究了不同细胞黏附分子(CAM)对细胞黏附、生长和增殖的影响。本综述通过使用描述黏附过程的计算模型等阻断药物和抑制剂来阻断黏附,提供了细胞黏附的一般原理。还提出了一些基于CAM与选定有机分子之间相互作用的总自由能最小值的理论模型。最终目的是找到有关如何(通过医学手段或物理方式)调节CTC表面来抑制癌症转移形成的信息。
ACS Omega. 2025-2-9
Crit Rev Oncol Hematol. 2021-11
Front Bioeng Biotechnol. 2024-5-27
Comput Methods Programs Biomed. 2025-6
Trends Cancer. 2022-10
Front Oncol. 2012-7-24
Commun Biol. 2024-5-23
Front Oncol. 2023-10-12
Nat Commun. 2022-10-19
Front Cell Dev Biol. 2022-8-30
Adv Pharm Bull. 2022-5